BioNTech SE and Pfizer Inc. announced on July 23, 2021, that the U.S. government had purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine, known as Comirnaty.
These doses are expected to be delivered from October 2021 through April 2022.
“As a long-term partner to the U.S. government in the fight against this (COVID-19) pandemic, we are proud of the impact of vaccination efforts across the country. Vaccines have been and will remain critical to protecting lives against this devastating disease,” said Albert Bourla, CEO, Pfizer, in a related press release.
“These additional doses will help the U.S. government ensure broad vaccine access into next year.”
The Pfizer-BioNTech COVID-19 Vaccine, based on BioNTech proprietary mRNA technology, was developed by BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union and the holder of emergency use authorizations or equivalent in the United States (jointly with Pfizer), Canada, and other countries in advance of a planned application for full marketing authorizations in these countries.